Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)

6 listopada 2026 zaktualizowane przez: Novartis Pharmaceuticals

Randomizowane, podwójnie ślepe, podwójnie pozorowane badanie w grupach równoległych, porównujące skuteczność i bezpieczeństwo remibrutynibu w porównaniu z teryflunomidem u uczestników z nawracającym stwardnieniem rozsianym, a następnie przedłużonym leczeniem otwartym remibrutynibem

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)

Przegląd badań

Status

Aktywny, nie rekrutujący

Warunki

Interwencja / Leczenie

Szczegółowy opis

The study CLOU064C12302 consists of an initial Core Part (CP) (maximum duration per participant of up to 30 months), followed by an Extension Part (EP, of up to 5 years duration) for eligible participants.

The Core Part is a randomized, double-blind, double-dummy, active comparator-controlled, fixed-dose, parallel-group, multi-center study in approximately 800 participants with relapsing multiple sclerosis (RMS).

The Extension Part is an open-label, single-arm, fixed-dose design in which eligible participants are treated with remibrutinib for up to 5 years.

A second study of identical design (CLOU064C12301) will be conducted simultaneously. Both studies will be conducted globally and data from the two studies will be pooled for some of the endpoints.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

1007

Faza

  • Faza 3

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

      • Pretoria, Afryka Południowa, 0041
        • Novartis Investigative Site
      • Rosebank, Afryka Południowa, 2196
        • Novartis Investigative Site
    • Free State
      • Bloemfontein, Free State, Afryka Południowa, 9301
        • Novartis Investigative Site
      • Buenos Aires, Argentyna, C1012AAR
        • Novartis Investigative Site
      • CABA, Argentyna, C1181ACH
        • Novartis Investigative Site
      • Córdoba, Argentyna, X5004CDT
        • Novartis Investigative Site
    • Mendoza Province
      • Bombal, Mendoza Province, Argentyna, M5500DXO
        • Novartis Investigative Site
    • Santa Fe Province
      • Rosario, Santa Fe Province, Argentyna, S2000BZL
        • Novartis Investigative Site
      • Rosario, Santa Fe Province, Argentyna, S2000DSW
        • Novartis Investigative Site
    • Tucumán Province
      • San Miguel de, Tucumán Province, Argentyna, T4000
        • Novartis Investigative Site
      • São Paulo, Brazylia, 01240-020
        • Novartis Investigative Site
    • Espírito Santo
      • Vitória, Espírito Santo, Brazylia, 29055-450
        • Novartis Investigative Site
    • Federal District
      • Brasília, Federal District, Brazylia, 70200-730
        • Novartis Investigative Site
    • Paraná
      • Curitiba, Paraná, Brazylia, 81210-310
        • Novartis Investigative Site
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brazylia, 90430-001
        • Novartis Investigative Site
      • Porto Alegre, Rio Grande do Sul, Brazylia, 90560-032
        • Novartis Investigative Site
      • Porto Alegre, Rio Grande do Sul, Brazylia, 90620-130
        • Novartis Investigative Site
    • Santa Catarina
      • Joinville, Santa Catarina, Brazylia, 89202-165
        • Novartis Investigative Site
      • Plovdiv, Bułgaria, 4002
        • Novartis Investigative Site
      • Sofia, Bułgaria, 1309
        • Novartis Investigative Site
      • Sofia, Bułgaria, 1431
        • Novartis Investigative Site
      • Sofia, Bułgaria, 1407
        • Novartis Investigative Site
      • Beijing, Chiny, 100034
        • Novartis Investigative Site
      • Shanghai, Chiny, 200025
        • Novartis Investigative Site
      • Shanghai, Chiny, 200040
        • Novartis Investigative Site
    • Hubei
      • Wuhan, Hubei, Chiny, 430030
        • Novartis Investigative Site
      • Wuhan, Hubei, Chiny, 430060
        • Novartis Investigative Site
    • Jiangsu
      • Nanjing, Jiangsu, Chiny, 210029
        • Novartis Investigative Site
    • Ningxia
      • Yinchuan, Ningxia, Chiny, 750004
        • Novartis Investigative Site
    • Shanxi
      • Taiyuan, Shanxi, Chiny, 030001
        • Novartis Investigative Site
    • Zhejiang
      • Hangzhou, Zhejiang, Chiny, 310016
        • Novartis Investigative Site
      • Hangzhou, Zhejiang, Chiny, 310006
        • Novartis Investigative Site
      • Wenzhou, Zhejiang, Chiny, 325000
        • Novartis Investigative Site
      • Zagreb, Chorwacja, 10000
        • Novartis Investigative Site
    • Croatia
      • Zagreb, Croatia, Chorwacja, 10000
        • Novartis Investigative Site
    • HRV
      • Split, HRV, Chorwacja, 21000
        • Novartis Investigative Site
      • Varaždin, HRV, Chorwacja, 42000
        • Novartis Investigative Site
    • Vukovar
      • Vukovar, Vukovar, Chorwacja, 32000
        • Novartis Investigative Site
      • Brno, Czechy, 602 00
        • Novartis Investigative Site
      • Hradec Králové, Czechy, 500 05
        • Novartis Investigative Site
      • Teplice, Czechy, 415 29
        • Novartis Investigative Site
      • Tallinn, Estonia, 11315
        • Novartis Investigative Site
      • Tartu, Estonia, 50406
        • Novartis Investigative Site
      • Caen, Francja, 14033
        • Novartis Investigative Site
      • Clermont-Ferrand, Francja, 63003
        • Novartis Investigative Site
      • Dijon, Francja, 21000
        • Novartis Investigative Site
      • Gonesse, Francja, 95500
        • Novartis Investigative Site
      • Grenoble, Francja, 38043
        • Novartis Investigative Site
      • Lille, Francja, 59037
        • Novartis Investigative Site
      • Lille, Francja, 59000
        • Novartis Investigative Site
      • Nice, Francja, 06000
        • Novartis Investigative Site
      • Nîmes, Francja, 30029
        • Novartis Investigative Site
      • Poissy, Francja, 78303
        • Novartis Investigative Site
      • Toulouse, Francja, 31059
        • Novartis Investigative Site
    • Haute Vienne
      • Limoges, Haute Vienne, Francja, 87000
        • Novartis Investigative Site
    • Val De Marne
      • Toulon, Val De Marne, Francja, 83800
        • Novartis Investigative Site
      • Athens, Grecja, 115 28
        • Novartis Investigative Site
      • Athens, Grecja, 115 26
        • Novartis Investigative Site
      • Chaïdári, Grecja, 124 62
        • Novartis Investigative Site
      • Ioannina, Grecja, 455 00
        • Novartis Investigative Site
      • Larissa, Grecja, 411 10
        • Novartis Investigative Site
      • Thessaloniki, Grecja, 532 46
        • Novartis Investigative Site
      • Thessaloniki, Grecja, 546 36
        • Novartis Investigative Site
      • Lleida, Hiszpania, 25198
        • Novartis Investigative Site
      • Madrid, Hiszpania, 28040
        • Novartis Investigative Site
      • Madrid, Hiszpania, 28009
        • Novartis Investigative Site
      • Málaga, Hiszpania, 29016
        • Novartis Investigative Site
      • Seville, Hiszpania, 41009
        • Novartis Investigative Site
      • Valencia, Hiszpania, 46026
        • Novartis Investigative Site
    • A Coruna
      • Santiago Compostela, A Coruna, Hiszpania, 15706
        • Novartis Investigative Site
    • Araba
      • Vitoria-Gasteiz, Araba, Hiszpania, 01009
        • Novartis Investigative Site
    • Barcelona
      • L'Hospitalet de Llobregat, Barcelona, Hiszpania, 08907
        • Novartis Investigative Site
    • Castille-La Mancha
      • Albacete, Castille-La Mancha, Hiszpania, 02006
        • Novartis Investigative Site
    • Catalonia
      • Barcelona, Catalonia, Hiszpania, 08003
        • Novartis Investigative Site
    • La Rioja
      • Logroño, La Rioja, Hiszpania, 26006
        • Novartis Investigative Site
    • Madrid
      • Pozuelo de Alarcón, Madrid, Hiszpania, 28223
        • Novartis Investigative Site
      • Torrejón de Ardoz, Madrid, Hiszpania, 28850
        • Novartis Investigative Site
    • Principality of Asturias
      • Gijón, Principality of Asturias, Hiszpania, 33394
        • Novartis Investigative Site
    • Valencia
      • Valencia, Valencia, Hiszpania, 46017
        • Novartis Investigative Site
    • Kerala
      • Kochi, Kerala, Indie, 682025
        • Novartis Investigative Site
    • Maharashtra
      • Pune, Maharashtra, Indie, 411013
        • Novartis Investigative Site
    • National Capital Territory of Delhi
      • New Delhi, National Capital Territory of Delhi, Indie, 110060
        • Novartis Investigative Site
    • Punjab
      • Amritsar, Punjab, Indie, 143006
        • Novartis Investigative Site
    • Telangana
      • Hyderabad, Telangana, Indie, 500082
        • Novartis Investigative Site
    • Uttar Pradesh
      • Lucknow, Uttar Pradesh, Indie, 226007
        • Novartis Investigative Site
    • West Bengal
      • Kolkata, West Bengal, Indie, 700017
        • Novartis Investigative Site
      • Fukuoka, Japonia, 8128582
        • Novartis Investigative Site
      • Niigata, Japonia, 9518520
        • Novartis Investigative Site
    • Aichi-ken
      • Nagoya, Aichi-ken, Japonia, 4668560
        • Novartis Investigative Site
    • Chiba
      • Chiba, Chiba, Japonia, 2608677
        • Novartis Investigative Site
      • Ichihara, Chiba, Japonia, 2990111
        • Novartis Investigative Site
    • Fukuoka
      • Fukuoka, Fukuoka, Japonia, 8100022
        • Novartis Investigative Site
    • Hokkaido
      • Sapporo, Hokkaido, Japonia, 0630005
        • Novartis Investigative Site
    • Hyōgo
      • Kobe, Hyōgo, Japonia, 6500017
        • Novartis Investigative Site
      • Nishinomiya, Hyōgo, Japonia, 663 8501
        • Novartis Investigative Site
    • Kanagawa
      • Isehara, Kanagawa, Japonia, 2591193
        • Novartis Investigative Site
      • Sagamihara, Kanagawa, Japonia, 2520375
        • Novartis Investigative Site
    • Kyoto
      • Kyoto, Kyoto, Japonia, 6168255
        • Novartis Investigative Site
    • Miyagi
      • Sendai, Miyagi, Japonia, 9838512
        • Novartis Investigative Site
    • Nara
      • Kashihara, Nara, Japonia, 6348522
        • Novartis Investigative Site
    • Osaka
      • Moriguchi, Osaka, Japonia, 5708507
        • Novartis Investigative Site
      • Suita, Osaka, Japonia, 5650871
        • Novartis Investigative Site
    • Saitama
      • Higashi-Matsuyama, Saitama, Japonia, 3550005
        • Novartis Investigative Site
    • Tokyo
      • Kodaira, Tokyo, Japonia, 1878551
        • Novartis Investigative Site
      • Shinjuku Ku, Tokyo, Japonia, 1628666
        • Novartis Investigative Site
      • Shinjuku Ku, Tokyo, Japonia, 1600023
        • Novartis Investigative Site
      • Shinjuku-ku, Tokyo, Japonia, 1608582
        • Novartis Investigative Site
      • tabashi City, Tokyo, Japonia, 1738610
        • Novartis Investigative Site
    • Alberta
      • Edmonton, Alberta, Kanada, T6G 2B7
        • Novartis Investigative Site
    • British Columbia
      • Burnaby, British Columbia, Kanada, V5G 2X6
        • Novartis Investigative Site
    • Nova Scotia
      • Halifax, Nova Scotia, Kanada, B3H 4K4
        • Novartis Investigative Site
    • Ontario
      • Ottawa, Ontario, Kanada, K1H 8L6
        • Novartis Investigative Site
    • Quebec
      • Lévis, Quebec, Kanada, G6W 0M5
        • Novartis Investigative Site
      • Montreal, Quebec, Kanada, H4A 3T2
        • Novartis Investigative Site
      • Québec, Quebec, Kanada, G1J 1Z4
        • Novartis Investigative Site
      • Saint-Jérôme, Quebec, Kanada, J7Z 5T3
        • Novartis Investigative Site
      • Mexico City, Meksyk, 14050
        • Novartis Investigative Site
      • Querétaro, Meksyk, 76070
        • Novartis Investigative Site
    • Chihuahua
      • Chihuahua City, Chihuahua, Meksyk, 31203
        • Novartis Investigative Site
    • Mexico City
      • Mexico City, Mexico City, Meksyk, 06700
        • Novartis Investigative Site
      • Essen, Niemcy, 45147
        • Novartis Investigative Site
      • Hamburg, Niemcy, 22179
        • Novartis Investigative Site
    • Baden-Wurttemberg
      • Freiburg im Breisgau, Baden-Wurttemberg, Niemcy, 79106
        • Novartis Investigative Site
      • Bialystok, Polska, 15-704
        • Novartis Investigative Site
      • Glogow Wielkopolski, Polska, 36-060
        • Novartis Investigative Site
      • Katowice, Polska, 40-081
        • Novartis Investigative Site
      • Katowice, Polska, 40-571
        • Novartis Investigative Site
      • Katowice, Polska, 40-686
        • Novartis Investigative Site
      • Katowice, Polska, 40-689
        • Novartis Investigative Site
      • Lublin, Polska, 20-701
        • Novartis Investigative Site
      • Wroclaw, Polska, 51-685
        • Novartis Investigative Site
      • Zabrze, Polska, 41-800
        • Novartis Investigative Site
    • Poznan
      • Plewiska, Poznan, Polska, 62-064
        • Novartis Investigative Site
      • Guaynabo, Portoryko, 00968
        • Caribbean Center for Clinical Research Inc
      • Braga, Portugalia, 4710-243
        • Novartis Investigative Site
      • Coimbra, Portugalia, 3004-561
        • Novartis Investigative Site
      • Leiria, Portugalia, 2410-197
        • Novartis Investigative Site
      • Lisbon, Portugalia, 1649-035
        • Novartis Investigative Site
      • Lisbon, Portugalia, 1169-050
        • Novartis Investigative Site
      • Matosinhos Municipality, Portugalia, 4454-513
        • Novartis Investigative Site
      • Santa Maria da Feira, Portugalia, 4520-211
        • Novartis Investigative Site
      • Campulung Muscel, Rumunia, 115100
        • Novartis Investigative Site
      • Constanța, Rumunia, 900591
        • Novartis Investigative Site
    • ROM
      • Brasov, ROM, Rumunia, 500123
        • Novartis Investigative Site
      • Constanța, ROM, Rumunia, 900123
        • Novartis Investigative Site
    • Arizona
      • Phoenix, Arizona, Stany Zjednoczone, 85018
        • Ctr for Neurology and Spine
    • California
      • Hanford, California, Stany Zjednoczone, 93230
        • Vladimir Royter MD APMC
      • Los Angeles, California, Stany Zjednoczone, 90073
        • VA Greater LA Healthcare System
      • West Hollywood, California, Stany Zjednoczone, 90048
        • Regina Berkovich MD PhD Inc
    • Colorado
      • Aurora, Colorado, Stany Zjednoczone, 80045
        • CU Anschutz Med Campus
      • Denver, Colorado, Stany Zjednoczone, 80210
        • Colorado Neurological Research PC
    • Connecticut
      • Stamford, Connecticut, Stany Zjednoczone, 06905
        • New England Institute for Clinical Research
    • District of Columbia
      • Washington D.C., District of Columbia, Stany Zjednoczone, 20007
        • Georgetown University Hospital
      • Washington D.C., District of Columbia, Stany Zjednoczone, 20007
        • Georgetown University Hospital Research
    • Florida
      • Bradenton, Florida, Stany Zjednoczone, 34209
        • Nova Clinical Research LLC
      • Gainesville, Florida, Stany Zjednoczone, 32610
        • University of Florida
      • Hollywood, Florida, Stany Zjednoczone, 33021
        • Memorial Healthcare System
      • Maitland, Florida, Stany Zjednoczone, 32751
        • Neurology Associates PA
      • Miami, Florida, Stany Zjednoczone, 33136
        • UM Department Of Neurology
      • Miami, Florida, Stany Zjednoczone, 33133
        • Gables Neurology
      • Naples, Florida, Stany Zjednoczone, 34105
        • Aqualane Clinical Research
      • Orlando, Florida, Stany Zjednoczone, 32803
        • Advent Health Orlando
      • Pembroke Pines, Florida, Stany Zjednoczone, 33024
        • Humanity Clinical Research
      • Pensacola, Florida, Stany Zjednoczone, 32514
        • Emerald Coast Neurology
      • Port Orange, Florida, Stany Zjednoczone, 32127
        • Brain and Spine Institute
      • Vero Beach, Florida, Stany Zjednoczone, 32960
        • Vero Beach Neurology
      • Winter Park, Florida, Stany Zjednoczone, 32789
        • Conquest Research
    • Indiana
      • Merrillville, Indiana, Stany Zjednoczone, 46410
        • Methodist Neuroscience Institute
    • Kansas
      • Kansas City, Kansas, Stany Zjednoczone, 66160
        • University of Kansas Hospital
    • Kentucky
      • Nicholasville, Kentucky, Stany Zjednoczone, 40356
        • Baptist Physicians Lexington
    • Louisiana
      • New Orleans, Louisiana, Stany Zjednoczone, 70121
        • Ochsner Clinic Foundation
    • Maryland
      • Frederick, Maryland, Stany Zjednoczone, 21702
        • Clinre Comprehensive Neurology
    • Massachusetts
      • Boston, Massachusetts, Stany Zjednoczone, 02111
        • Tufts Medical Center
    • Missouri
      • Kansas City, Missouri, Stany Zjednoczone, 64128
        • Kansas City VA Medical Center
    • New York
      • Patchogue, New York, Stany Zjednoczone, 11772
        • South Shore Neurologic Associates
    • North Carolina
      • Chapel Hill, North Carolina, Stany Zjednoczone, 27599-9500
        • University Of NC At Chapel Hill
      • Charlotte, North Carolina, Stany Zjednoczone, 28210
        • Piedmont HealthCare
    • Ohio
      • Columbus, Ohio, Stany Zjednoczone, 43235
        • The Boster Ctr for MS
      • Dayton, Ohio, Stany Zjednoczone, 45408
        • Neurology Diagnostics Inc
    • Pennsylvania
      • Hershey, Pennsylvania, Stany Zjednoczone, 17033
        • Penn State Hershey Medical Center
    • South Carolina
      • Greenville, South Carolina, Stany Zjednoczone, 29605
        • Premier Neurology
      • Old Point Station, South Carolina, Stany Zjednoczone, 29707
        • Metrolina Neurological Associates PA
    • Tennessee
      • Knoxville, Tennessee, Stany Zjednoczone, 37922
        • Sibyl Wray MD Neurology PC
    • Texas
      • Dallas, Texas, Stany Zjednoczone, 75231
        • Carum Research
      • El Paso, Texas, Stany Zjednoczone, 79935
        • Med Research Inc
      • Frisco, Texas, Stany Zjednoczone, 75035
        • Lone Star Neurology
      • San Antonio, Texas, Stany Zjednoczone, 78258
        • Lonestar Neurology of San Antonio
      • San Antonio, Texas, Stany Zjednoczone, 78229
        • UT Health MARC Medical Arts and Research Center
      • Sherman, Texas, Stany Zjednoczone, 75092
        • Texas Institute for Neurological Disorders
      • Temple, Texas, Stany Zjednoczone, 76508
        • Baylor Scott and White
    • Washington
      • Seattle, Washington, Stany Zjednoczone, 98101
        • Virginia Mason Medical Centre
      • Seattle, Washington, Stany Zjednoczone, 98133
        • University of Washington MS Clinic
    • West Virginia
      • Crab Orchard, West Virginia, Stany Zjednoczone, 25827
        • Elligo Health Research
    • Wisconsin
      • Milwaukee, Wisconsin, Stany Zjednoczone, 53226
        • Medical College of Wisconsin
      • Milwaukee, Wisconsin, Stany Zjednoczone, 53215
        • Ascension St Francis Center
      • Stockholm, Szwecja, 102 35
        • Novartis Investigative Site
      • Banská Bystrica, Słowacja, 975 17
        • Novartis Investigative Site
      • Banská Bystrica, Słowacja, 974 04
        • Novartis Investigative Site
      • Bratislava, Słowacja, 833 05
        • Novartis Investigative Site
      • Celje, Słowenia, 3000
        • Novartis Investigative Site
      • Ljubljana, Słowenia, 1000
        • Novartis Investigative Site
    • Slovenia
      • Maribor, Slovenia, Słowenia, 2000
        • Novartis Investigative Site
      • Konya, Turcja (Türkiye), 42130
        • Novartis Investigative Site
    • Atakum
      • Samsun, Atakum, Turcja (Türkiye), 55200
        • Novartis Investigative Site
    • Balcova
      • Izmir, Balcova, Turcja (Türkiye), 35340
        • Novartis Investigative Site
    • Fatih
      • Istanbul, Fatih, Turcja (Türkiye), 34098
        • Novartis Investigative Site
      • Istanbul, Fatih, Turcja (Türkiye), 34093
        • Novartis Investigative Site
    • Karabaglar
      • Izmir, Karabaglar, Turcja (Türkiye), 35150
        • Novartis Investigative Site
    • Kocaeli
      • Köseköy, Kocaeli, Turcja (Türkiye), 41380
        • Novartis Investigative Site
    • Melikgazi
      • Kayseri, Melikgazi, Turcja (Türkiye), 38039
        • Novartis Investigative Site
    • Nilufer
      • Bursa, Nilufer, Turcja (Türkiye), 16140
        • Novartis Investigative Site
    • Pendik
      • Istanbul, Pendik, Turcja (Türkiye), 34899
        • Novartis Investigative Site
    • Sancaktepe
      • Istanbul, Sancaktepe, Turcja (Türkiye), 34785
        • Novartis Investigative Site
      • Naples, Włochy, 80138
        • Novartis Investigative Site
    • BR
      • Brindisi, BR, Włochy, 72100
        • Novartis Investigative Site
    • FG
      • Foggia, FG, Włochy, 71122
        • Novartis Investigative Site
    • IS
      • Pozzilli, IS, Włochy, 86077
        • Novartis Investigative Site
    • ME
      • Messina, ME, Włochy, 98124
        • Novartis Investigative Site
    • MO
      • Modena, MO, Włochy, 41126
        • Novartis Investigative Site
    • PV
      • Pavia, PV, Włochy, 27100
        • Novartis Investigative Site
    • TO
      • Orbassano, TO, Włochy, 10043
        • Novartis Investigative Site
    • Invernesshire
      • Inverness, Invernesshire, Zjednoczone Królestwo, IV2 3RE
        • Novartis Investigative Site
    • Kent
      • Canterbury, Kent, Zjednoczone Królestwo, CT1 3NG
        • Novartis Investigative Site

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 55 lat (Dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • 18 to 55 years of age
  • Diagnosis of RMS according to the 2017 McDonald diagnostic criteria
  • At least: 1 documented relapse within the previous year. OR 2 documented relapses within the previous 2 years, OR 1 active Gadolinium (Gd)-enhancing lesion in the 12 months.
  • EDSS score of 0 to 5.5 (inclusive)
  • Neurologically stable within 1 month

Exclusion Criteria:

  • Diagnosis of primary progressive multiple sclerosis (PPMS)

  • Disease duration of more than 10 years in participants with EDSS score of 2 or less at screening

  • History of clinically significant CNS disease other than MS

  • Ongoing substance abuse (drug or alcohol)

  • History of malignancy of any organ system (other than complete resection of localized basal cell carcinoma of the skin or in situ cervical cancer),

  • Participants with history of confirmed Progressive Multifocal Leukoencephalopathy (PML) or Neurological symptoms consistent with PML

  • suicidal ideation or behavior

  • Evidence of clinically significant cardiovascular, neurological, psychiatric, pulmonary , renal, hepatic, endocrine, metabolic, hematological disorders or gastrointestinal disease that can interfere with interpretation of the study results or protocol adherence

  • Participants who have had a splenectomy

  • Active clinically significant systemic bacterial, viral, parasitic or fungal infections

  • Positive results for syphilis or tuberculosis testing

  • Uncontrolled disease states, such as asthma, or inflammatory bowel disease, where flares are commonly treated with oral or parenteral corticosteroids

  • Active, chronic disease of the immune system (including stable disease treated with immune therapy (e.g. Leflunomide, Methotrexate)) other than MS (e.g. rheumatoid arthritis, systemic lupus erythematosus, etc.) with the exception of well-controlled diabetes or thyroid disorder.

  • Participants with a known immunodeficiency syndrome (AIDS, hereditary immune deficiency, drug induced immune deficiency), or tested positive for HIV antibody

  • History or current treatment for hepatic disease including but not limited to acute or chronic hepatitis, cirrhosis (including all Child-Pugh classes) or hepatic failure or any chronic liver or biliary disease.

  • History of severe renal disease or creatinine level

  • Participants at risk of developing or having reactivation of hepatitis

  • Hematology parameters at screening:

    • Hemoglobin: < 10 g/dl (<100g/L)
    • Platelets: < 100000/mm3 (<100 x 109/L)
    • Absolute lymphocyte count < 800/mm3 (<0.8 x 109/L)
    • White blood cells: <3 000/mm3 (<3.0 x 109/L)
    • Neutrophils: < 1 500/mm3 (<1.5 x 109/L)
    • B-cell count < 50% lower limit of normal (LLN) or total IgG & total IgM < LLN (only required for participants who had a history of receiving B-cell therapies, such as rituximab, ocrelizumab or ofatumumab, prior to screening)
  • History or current diagnosis of significant ECG abnormalities

  • Resting QTcF ≥450 msec (male) or ≥460 msec (female) at pre-treatment as per central ECG reading at screening visit

  • Use of other investigational drugs

  • Requirement for anticoagulant medication or use of dual anti-platelet therapy Significant bleeding risk or coagulation disorders,

  • History of gastrointestinal bleeding

  • Major surgery within 8 weeks prior to screening

  • History of hypersensitivity to any of the study drugs or excipients

  • Pregnant or nursing (lactating) female participants, prior to randomization

  • Women of childbearing potential not using highly effective contraception

  • Sexually active males not agreeing to use condom

  • Have received any live or live-attenuated vaccines within 6 weeks of randomization or requirement to receive these vaccinations during study

  • Use of strong CYP3A4 inhibitors or use of moderate or strong CYP3A4 inducers within two weeks prior to randomization

Inclusion to Extension part:

• Participants who complete the Core Part of the study on double-blind study treatment and conduct the Accelerated Elimination Procedure (AEP)

Other inclusion and exclusion criteria may apply.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Podwójnie

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Remibrutinib - Core

Remibrutinib tablet and matching placebo of teriflunomide capsule

tablet taken orally

Inne nazwy:
  • LOU064
Aktywny komparator: Teriflunomide - Core

Teriflunomide capsule and matching placebo remibrutinib tablet

capsule taken orally

Eksperymentalny: Remibrutinib - Extension

Participants on remibrutinib in Core will continue on remibrutinib tablet

tablet taken orally

Inne nazwy:
  • LOU064
Eksperymentalny: Remibrutinib - Extension (on teriflunomide in Core)

Participants on teriflunomide in Core will switch to remibrutinib tablet

tablet taken orally

Inne nazwy:
  • LOU064

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Annualized relapse rate (ARR) of confirmed relapses [Core Part]
Ramy czasowe: From Baseline, up to 30 months

ARR is the average number of confirmed MS relapses in a year

From Baseline, up to 30 months

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Time to 3-month confirmed disability progression (3mCDP) on Expanded Disability Status Scale (EDSS) [Core Part] (pooled data)
Ramy czasowe: Baseline up to 30 months

Time to 3-month confirmed disability progression (3mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 3 months

Baseline up to 30 months
Time to 6-month confirmed disability progression (6mCDP) on EDSS [Core Part] (pooled data)
Ramy czasowe: Baseline up to 30 months

Time to 6-month confirmed disability progression (6mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 6 months

Baseline up to 30 months
Annualized rate of new or enlarging T2 lesion [Core Part]
Ramy czasowe: Baseline up to 30 months

Number of new/newly enlarged T2 lesions per year

Baseline up to 30 months
Neurofilament light chain (Nfl) [Core Part]
Ramy czasowe: Baseline up to 30 months

Neurofilament light chain (NfL) concentration in serum

Baseline up to 30 months
Number of Gd-enhancing T1 lesions per MRI scan [Core Part]
Ramy czasowe: Baseline up to 30 months

Average number of Gd-enhancing T1 lesions per scan

Baseline up to 30 months
Percentage of participants with No Evidence of Disease Activity-3 (NEDA-3) [Core Part] (pooled data)
Ramy czasowe: Baseline up to 30 months

Percentage of participants with No Evidence of Disease Activity-3 (NEDA-3), as assessed by absence of confirmed MS relapses, 6mCDP and new/enlarging T2 lesions on MRI

Baseline up to 30 months
Time to first confirmed relapse [Core Part]
Ramy czasowe: Baseline up to 30 months

Change in the Expanded Disability Status Scale (EDSS), an increase of at least 0.5 points on the EDSS (total) score, or an increase of at least 1 point on at least two functional scores (FSs), or an increase of at least 2 points on at least one FS, excluding changes involving bowel/bladder or cerebral FS, compared to the previous available rating.

Baseline up to 30 months
Time to 6-month confirmed disability improvement (6mCDI) on EDSS [Core Part] (pooled data)
Ramy czasowe: Baseline up to 30 months

Decrease in Expanded Disability Status Scale Score (EDSS) which is sustained for at least 6 months

Baseline up to 30 months
Time to 3-months confirmed disability progression (3mCDP) and 6-month confirmed disability progression (6mCDP) independent of relapse activity (PIRA) [Core Part] (pooled data)
Ramy czasowe: Baseline up to 30 months

Time to 3-month confirmed disability progression (3mCDP) and 6-month confirmed disability progression (6mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 3 months or 6 months, respectively, without an on-study relapse before or on the day of a progression eve

Baseline up to 30 months
Change from baseline in the Symbol Digit Modalities Test (SDMT) [Core Part] (pooled data)
Ramy czasowe: Baseline up to 30 months

Symbol Digit Modalities Test (SDMT), an array of symbols paired with empty spaces, measures processing in speed; participants verbally match the number for each symbol as rapidly as possible. The score is the number of correctly coded items in 90 seconds. Higher scores indicate improvement. Lower scores indicate worsening

Baseline up to 30 months
Time to 6-month confirmed worsening by at least 20% in the Timed 25-foot walk test (T25FW) [Core Part] (pooled data)
Ramy czasowe: Baseline, up to 30 months

The patient walking speed to cover 25-foot distance is recorded in seconds. Longer time indicates poorer lower limb function. 20% worsening is defined as 20% increase from baseline T25FW score

Baseline, up to 30 months
Time to 6-month confirmed worsening by at least 20% in the Timed 9-hole peg test (9HPT) (pooled data) [Core Part] (pooled data)
Ramy czasowe: Baseline up to 30 months

The patient's right and left arm function to peg 9 holes measured in seconds. Longer time indicates poorer upper limb function. 20% worsening is defined as 20% increase from baseline 9HPT score in at least one hand (average of two trials per hand)

Baseline up to 30 months
Time to composite 6-month confirmed disability Progression (CDP) [Core Part] (pooled data)
Ramy czasowe: Baseline up to 30 months

The composite involves CDP and worsening by at least 20% in T25FW and 9HPT

Baseline up to 30 months
Change from Baseline in T2 lesion volume [Core Part]
Ramy czasowe: Baseline up to 30 months

Change from baseline in total T2 lesion volume.

Baseline up to 30 months
Change from baseline in Multiple Sclerosis Impact Scale (MSIS-29) [Core Part]
Ramy czasowe: Baseline up to 30 months

29-item, self-administered questionnaire that includes 2 domains, physical and psychological. Responses are captured on a 4-point scale ranging from "not at all" (1) to "extremely" (4), where higher scores reflect greater impact on day to day life

Baseline up to 30 months
Number of participants with Adverse events and Serious adverse events(SAE) [Core Part]
Ramy czasowe: Baseline up to 30 months

Adverse events and SAEs including clinically significant, laboratory data, vital signs, electrocardiogram (ECG), Columbia Suicide Severity Rating

Baseline up to 30 months
Pharmacokinetics of remibrutinib [Core Part]
Ramy czasowe: Month 1, Month 6

Blood concentrations of remibrutinib

Month 1, Month 6
Number of participants with Adverse events and Serious adverse events (SAE) [Extension Part]
Ramy czasowe: Day 1 Extension up to 5 years

Adverse events and SAEs including clinically significant, laboratory data, vital signs, electrocardiogram (ECG), Columbia Suicide Severity Rating

Day 1 Extension up to 5 years
Annualized relapse rate (ARR) of confirmed relapses [Extension Part]
Ramy czasowe: Day 1 Extension up to 5 years

ARR is the average number of confirmed MS relapses in a year

Day 1 Extension up to 5 years
Annualized rate of new or enlarging T2 lesion [Extension Part]
Ramy czasowe: Day 1 Extension up to 5 years

Number of new/newly enlarged T2 lesions per year

Day 1 Extension up to 5 years
Time to 6-month confirmed disability progression (6mCDP) on EDSS [Extension Part]
Ramy czasowe: Day 1 Extension up to 5 years

Time to 6-month confirmed disability progression (6mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 6 months

Day 1 Extension up to 5 years
Change from baseline in the Symbol Digit Modalities Test (SDMT) [Extension Part]
Ramy czasowe: Day 1 Extension up to 5 years

Symbol Digit Modalities Test (SDMT), an array of symbols paired with empty spaces, measures processing in speed; participants verbally match the number for each symbol as rapidly as possible. The score is the number of correctly coded items in 90 seconds. Higher scores indicate improvement. Lower scores indicate worsening

Day 1 Extension up to 5 years
Neurofilament light chain (NfL) [Extension Part]
Ramy czasowe: Day 1 Extension up to 5 years

Neurofilament light chain (NfL) concentration in serum

Day 1 Extension up to 5 years
Change from baseline in Multiple Sclerosis Impact Scale (MSIS-29) [Extension Part]
Ramy czasowe: Day 1 Extension up to 5 years

29-item, self-administered questionnaire that includes 2 domains, physical and psychological. Responses are captured on a 4-point scale ranging from "not at all" (1) to "extremely" (4), where higher scores reflect greater impact on day to day life

Day 1 Extension up to 5 years

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Śledczy

  • Dyrektor Studium: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

13 grudnia 2021

Zakończenie podstawowe (Rzeczywisty)

22 lipca 2026

Ukończenie studiów (Szacowany)

30 października 2030

Daty rejestracji na studia

Pierwszy przesłany

1 grudnia 2021

Pierwszy przesłany, który spełnia kryteria kontroli jakości

1 grudnia 2021

Pierwszy wysłany (Rzeczywisty)

14 grudnia 2021

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

12 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

6 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • CLOU064C12302
  • 2023-509372-41-00 (Identyfikator rejestru: EU CTIS)
  • 2023 (Grant/umowa NIH USA)

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .